Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenji Maeda

Showing results (201-210 of 233) with videos related to

Pageof 24
Sort By:
Antimicrobial Agents and Chemotherapy|July 24, 2013
P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moietyRavikiran S Yedidi, Kenji Maeda, W Sean Fyvie, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 8, 2013
Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptideSarah I Daniels, Erin E Soule, Katharine S Davidoff, et al.
International Journal of Cancer|December 19, 2022
Chronic acidosis rewires cancer cell metabolism through PPARα signalingMichala G Rolver, Lya K K Holland, Muthulakshmi Ponniah, et al.
Mbio|August 22, 2020
GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 InfectionShin-Ichiro Hattori, Nobuyo Higshi-Kuwata, Jakka Raghavaiah, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 21, 2014
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulatorKenji Maeda, Haruhiko Sugino, Hitomi Akazawa, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitroYasuhiro Koh, Hirotomo Nakata, Kenji Maeda, et al.
Journal of Medicinal Chemistry|August 18, 2006
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistanceArun K Ghosh, Perali Ramu Sridhar, Sofiya Leshchenko, et al.
Hepatology (Baltimore, Md.)|July 1, 2015
4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virusYuki Takamatsu, Yasuhito Tanaka, Satoru Kohgo, et al.
The Journal of Infectious Diseases|September 27, 2023
Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched AnalysisShohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
Antimicrobial Agents and Chemotherapy|April 23, 2014
A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIVRavikiran S Yedidi, Harisha Garimella, Manabu Aoki, et al.
Pageof 24

Showing results (201-210 of 233) with videos related to

Sort By:
Pageof 24
Antimicrobial Agents and Chemotherapy|July 24, 2013
P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moietyRavikiran S Yedidi, Kenji Maeda, W Sean Fyvie, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 8, 2013
Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptideSarah I Daniels, Erin E Soule, Katharine S Davidoff, et al.
International Journal of Cancer|December 19, 2022
Chronic acidosis rewires cancer cell metabolism through PPARα signalingMichala G Rolver, Lya K K Holland, Muthulakshmi Ponniah, et al.
Mbio|August 22, 2020
GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 InfectionShin-Ichiro Hattori, Nobuyo Higshi-Kuwata, Jakka Raghavaiah, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 21, 2014
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulatorKenji Maeda, Haruhiko Sugino, Hitomi Akazawa, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2003
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitroYasuhiro Koh, Hirotomo Nakata, Kenji Maeda, et al.
Journal of Medicinal Chemistry|August 18, 2006
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistanceArun K Ghosh, Perali Ramu Sridhar, Sofiya Leshchenko, et al.
Hepatology (Baltimore, Md.)|July 1, 2015
4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virusYuki Takamatsu, Yasuhito Tanaka, Satoru Kohgo, et al.
The Journal of Infectious Diseases|September 27, 2023
Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched AnalysisShohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
Antimicrobial Agents and Chemotherapy|April 23, 2014
A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIVRavikiran S Yedidi, Harisha Garimella, Manabu Aoki, et al.
Pageof 24